<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33524620</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Characterization of antibodies in human immunoglobulin products from different regions worldwide.</ArticleTitle><Pagination><StartPage>610</StartPage><EndPage>616</EndPage><MedlinePgn>610-616</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2021.01.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(21)00041-2</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The antibody levels against a broad spectrum of pathogens were assessed in commercial intravenous immunoglobulin (IVIG) manufactured from pooled plasma obtained from different global regions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-four IVIG commercial lots from eight manufacturers corresponding to 12 brands were analyzed. The plasma was collected in 10 countries/regions. Depending on each pathogen, antibody levels were measured using specific commercial IgG-specific enzyme immunoassay kits or by cell culture neutralization test and guinea pig skin neutralization test. A principal component analysis was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For polio and diphtheria (reference markers of the US authorities), all IVIGs had relevant titers in accordance with reference levels. IVIGs from Canada, Australia, and the USA were positive for titers against globally distributed pathogens or those under vaccination programs in the developed world (parainfluenza, Epstein-Barr, varicella-zoster, influenza B, parvovirus B19, and measles viruses). IVIG from Taiwan and Hong Kong showed low antibody titers for these pathogens but high titers for Pseudomonas aeruginosa. IVIG from India had high titers for pathogens frequently found in developing countries (West Nile, dengue, chikungunya, and hepatitis E viruses and Streptococcus pneumoniae). IVIGs from Argentina, Spain, Israel, and Czechia showed intermediate antibody concentrations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The antibody profile in IVIG was greatly influenced by regional characteristics including climate, vaccination programs, and the prevalence of pathogens in the different countries and regions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grifols, Research and Development, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzo</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Grifols, Research and Development, Barcelona, Spain. Electronic address: nuria.marzo@grifols.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pons</LastName><ForeName>Berta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Grifols, Research and Development, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maduell</LastName><ForeName>Pau</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Grifols, Research and Development, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Maite</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grifols, Research and Development, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grancha</LastName><ForeName>Salvador</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Grifols, Research and Development, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000569" MajorTopicYN="N" Type="Geographic">Americas</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N" Type="Geographic">Asia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody titer</Keyword><Keyword MajorTopicYN="N">Blood plasma</Keyword><Keyword MajorTopicYN="N">Intravenous immunoglobulin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33524620</ArticleId><ArticleId IdType="pmc">PMC7844383</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2021.01.034</ArticleId><ArticleId IdType="pii">S1201-9712(21)00041-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anukumar B., Sapkal G.N., Tandale B.V., Balasubramanian R., Gangale D. West Nile encephalitis outbreak in Kerala, India, 2011. J Clin Virol. 2014;61:152&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">24985196</ArticleId></ArticleIdList></Reference><Reference><Citation>Audet S., Virata-Theimer M.L., Beeler J.A., Scott D.E., Frazier D.J., Mikolajczyk M.G., Eller N., Chen F.M., Yu M.Y. Measles-virus-neutralizing antibodies in intravenous immunoglobulins. J Infect Dis. 2006;194:781&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">16941344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzo J., Jorquera J.I. Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. Expert Rev Anti Infect Ther. 2017;15:585&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">28480779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruton O.C. Agammaglobulinemia. Pediatrics. 1952;9:722&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">14929630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W., Liu X., Bai T., Fan H., Hong K., Song H., Han Y., Lin L., Ruan L., Li T. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum Infect Dis. 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111600</ArticleId><ArticleId IdType="pubmed">32258207</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez J.M., Romero C., Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy. 2020;12:571&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222542</ArticleId><ArticleId IdType="pubmed">32397847</ArticleId></ArticleIdList></Reference><Reference><Citation>Farcet M.R., Planitzer C.B., Stein O., Modrof J., Kreil T.R. Hepatitis A virus antibodies in immunoglobulin preparations. J Allergy Clin Immunol. 2010;125:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">19962745</ArticleId></ArticleIdList></Reference><Reference><Citation>Farcet M.R., Karbiener M., Rabel P.O., Schirmer A., Ilk R., Kreil T.R. Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States. Vaccine. 2019;37:3151&#x2013;3153.</Citation><ArticleIdList><ArticleId IdType="pubmed">31060953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidding H.F., Backhouse J.L., Gilbert G.L., Burgess M.A. National serosurvey of poliovirus immunity in Australia, 1996-99. Aust N Z J Public Health. 2005;29:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15782872</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldacker S., Witte T., Huzly D., Schlesier M., Peter H.H., Warnatz K. Analysis of specific IgG titers against tick-borne encephalitis in patients with primary antibody deficiency under immunoglobulin substitution therapy: impact of plasma donor origin. Front Immunol. 2014;5:675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283645</ArticleId><ArticleId IdType="pubmed">25601868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajizadeh M. Socioeconomic inequalities in child vaccination in low/middle-income countries: what accounts for the differences? J Epidemiol Community Health. 2018;72:719&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">29581228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong D.K., Tremoulet A.H., Burns J.C., Lewis D.B. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J. 2011;30:67&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044211</ArticleId><ArticleId IdType="pubmed">20724956</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorquera J.I. Flebogamma&#xae; 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy. Clin Exper Immunol. 2009;157:17&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715432</ArticleId><ArticleId IdType="pubmed">19630865</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller M.A., Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13:602&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88952</ArticleId><ArticleId IdType="pubmed">11023960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota-Koketsu R., Yunoki M., Okuno Y., Ikuta K. Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010. Biologics. 2012;6:245&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413397</ArticleId><ArticleId IdType="pubmed">22888217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemieux R., Bazin R., Neron S. Therapeutic intravenous immunoglobulins. Molecular Immunology. 2005;42:839&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829272</ArticleId></ArticleIdList></Reference><Reference><Citation>Leshem E., Bin H., Shalom U., Perkin M., Schwartz E. Risk for emergence of dengue and chikungunya virus in Israel. Emerg Infect Dis. 2012;18:345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310478</ArticleId><ArticleId IdType="pubmed">22305194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., Zhou H., Hu Z., Zhou W., Zhao L., Chen J., Meng Y., Wang J., Lin Y., Yuan J., Xie Z., Ma J., Liu W.J., Wang D., Xu W., Holmes E.C., Gao G.F., Wu G., Chen W., Shi W., Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Macartney K., Gidding H.F., Trinh L., Wang H., Dey A., Hull B., Orr K., McRae J., Richmond P., Gold M., Crawford N., Kynaston J.A., McIntyre P., Wood N. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. JAMA Pediatrics. 2017;171:992&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710620</ArticleId><ArticleId IdType="pubmed">28806450</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranich A.M., Rajnik M. Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations. Pediatrics. 2009;124 e484-e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19706589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Miescher S.M., Huber T.M., Kuhne M., Lieby P., Snydman D.R., Vensak J.L., Berger M. In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins. Vox Sang. 2015;109:71&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">25766313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikolajczyk M.G., Concepcion N.F., Wang T., Frazier D., Golding B., Frasch C.E., Scott D.E. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11:1158&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524781</ArticleId><ArticleId IdType="pubmed">15539522</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakae T., Nakajima T., Nagai H., Watanabe M., Yokoyama K. [Protective effect and antibody titer of intravenous immunoglobulin (IVIG) against clinical isolates of opportunistic bacteria] Yakugaku Zasshi. 1994;114:972&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">7869237</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobre F.A., Gonzalez I.G., Simao R.M., de Moraes Pinto M.I., Costa-Carvalho B.T. Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study. BMC Immunol. 2014;15:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074853</ArticleId><ArticleId IdType="pubmed">24952415</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez E.E., Orange J.S., Bonilla F., Chinen J., Chinn I.K., Dorsey M., El-Gamal Y., Harville T.O., Hossny E., Mazer B., Nelson R., Secord E., Jordan S.C., Stiehm E.R., Vo A.A., Ballow M. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139 S1-s46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28041678</ArticleId></ArticleIdList></Reference><Reference><Citation>Pidwirny M.  2nd Edition. 2006. Climate Classification and Climatic Regions of the World. Fundamentals of Physical Geography. Available at:  http://www.physicalgeography.net/fundamentals/7v.html. Last accessed: November 9, 2020.</Citation></Reference><Reference><Citation>Pison G.  2019. World Economic Forum. Which countries have the most immigrants? Available at:  https://www.weforum.org/agenda/2019/03/which-countries-have-the-most-immigrants-51048ff1f9/. Last accessed: November 9, 2020.</Citation></Reference><Reference><Citation>Planitzer C.B., Farcet M.R., Schiff R.I., Ochs H.D., Kreil T.R. Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin. J Med Virol. 2011;83:305&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181927</ArticleId></ArticleIdList></Reference><Reference><Citation>Planitzer C.B., Saemann M.D., Gajek H., Farcet M.R., Kreil T.R. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation. 2011;92:267&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">21659947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pybus O.G., Tatem A.J., Lemey P. Virus evolution and transmission in an ever more connected world. Proc Biol Sci. 2015;282</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707738</ArticleId><ArticleId IdType="pubmed">26702033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabel P.O., Planitzer C.B., Farcet M.R., Orlinger K.K., Ilk R., Barrett P.N., Kreil T.R. Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010. Euro Surveill. 2011;16</Citation><ArticleIdList><ArticleId IdType="pubmed">21435324</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabel P.O., Planitzer C.B., Farcet M.R., Kreil T.R. Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations. Clin Vaccine Immunol. 2012;19:623&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318267</ArticleId><ArticleId IdType="pubmed">22379062</ArticleId></ArticleIdList></Reference><Reference><Citation>Radosevich M., Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98:12&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">19660029</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder H.W., Jr., Dougherty C.J. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012;40:601&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501191</ArticleId><ArticleId IdType="pubmed">22968971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibaguchi H., Yamamoto T., Kuroki M., Futagami K. Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations. Yakugaku Zasshi. 2010;130:977&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">20606378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan J.S., Selleck P.W., Downton T., Boehm I., Axell A.M., Ayob Y., Kapitza N.M., Dyer W., Fitzgerald A., Walsh B., Lynch G.W. Heterosubtypic anti-avian H5N1 influenza antibodies in intravenous immunoglobulins from globally separate populations protect against H5N1 infection in cell culture. J Mol Genet Med. 2009;3:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805843</ArticleId><ArticleId IdType="pubmed">20076794</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X., Jiang Z., Ma Q., Liu Q., Lu X., Liu W., Liao X., Zhou R., Su X., Luo Q. Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. J Thorac Dis. 2016;8:803&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842828</ArticleId><ArticleId IdType="pubmed">27162653</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations Development Programme . 2019. Human Development Report. Available at:  http://hdr.undp.org/sites/default/files/hdr2019.pdf. Las accessed: November 9, 2020.</Citation></Reference><Reference><Citation>US Food and Drug Administration . 2020. CFR - Code of Federal Regulations. Title 21: Food and Drugs; Volume 7; Chapter I: Food and Drug Administration Department Of Health And Human Services; Subchapter F: Biologics; Part 640: Additional Standards for Human Blood and Blood Products; Subpart J: Immune Globulin (Human); Section 640.104: Potency. Updated April 1, 2019. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=640.104. Last accessed: November 9.</Citation></Reference><Reference><Citation>US Pharmacopoeia . 2017. USP Official Monograph (USP 40): Immune globulin.</Citation></Reference><Reference><Citation>Vani J., Elluru S., Negi V.S., Lacroix-Desmazes S., Kazatchkine M.D., Bayry J., Kaveri S.V. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7:440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">18558359</ArticleId></ArticleIdList></Reference><Reference><Citation>von Behring E., Kitasato S. Ueber das zustandekommen der diphtherie-immunit&#xe4;t und der tetanus-immunit&#xe4;t bei thieren. Dtsch Med Wochenschr. 1890;16:1113&#x2013;1114.</Citation></Reference><Reference><Citation>Weeke-Luttmann M., Schmidt I., Fenyves A., von W.G., Fischer L. [Neutralizing virus antibodies in human immunoglobulins for intravenous use] Immun Infekt. 1984;12:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">6090309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Wang H.C., Wang K.T., Yang-Chih S.D., Lo C.F., Wang D.Y. Analyzing titers of antibodies against bacterial and viral antigens, and bacterial toxoids in the intravenous immunoglobulins utilized in Taiwan. Biologicals. 2013;41:88&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">23149017</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Cao S., Li Q., Chen E., Dong H., Zhang W., Yang L., Fu S., Wang R. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81:318&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151471</ArticleId><ArticleId IdType="pubmed">32283154</ArticleId></ArticleIdList></Reference><Reference><Citation>Young M.K., Bertolini J., Kotharu P., Maher D., Cripps A.W. Do Australian immunoglobulin products meet international measles antibody titer standards? Hum Vaccin Immunother. 2017;13:607&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360119</ArticleId><ArticleId IdType="pubmed">27763809</ArticleId></ArticleIdList></Reference><Reference><Citation>Young M.K., Bertolini J., Kotharu P., Maher D., Cripps A.W. Rubella antibodies in Australian immunoglobulin products. Hum Vaccin Immunother. 2017;13:1952&#x2013;1955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557226</ArticleId><ArticleId IdType="pubmed">28604142</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>